227 related articles for article (PubMed ID: 22426469)
1. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
2. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
4. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
5. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
7. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
8. Tannin inhibits HIV-1 entry by targeting gp41.
Lü L; Liu SW; Jiang SB; Wu SG
Acta Pharmacol Sin; 2004 Feb; 25(2):213-8. PubMed ID: 14769212
[TBL] [Abstract][Full Text] [Related]
9. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
10. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
[TBL] [Abstract][Full Text] [Related]
11. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
12. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
[TBL] [Abstract][Full Text] [Related]
13. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
14. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
15. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Gonzalez E; Ballana E; Clotet B; Esté JA
AIDS; 2011 Aug; 25(13):1557-83. PubMed ID: 21572303
[TBL] [Abstract][Full Text] [Related]
16. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors.
Wang C; Shi W; Cai L; Lu L; Wang Q; Zhang T; Li J; Zhang Z; Wang K; Xu L; Jiang X; Jiang S; Liu K
J Med Chem; 2013 Mar; 56(6):2527-39. PubMed ID: 23458727
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
[TBL] [Abstract][Full Text] [Related]
19. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
Maerz AL; Drummer HE; Wilson KA; Poumbourios P
J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
